Product Description
Silexan (WS¨1265) in patients with a major depressive episode of mild to moderate severity (Sourced from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000688-22/DE)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dr. Willmar Schwabe
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2020-000688-22 | P3 |
Active, not recruiting |
Depressive Disorder, Major |
2023-06-16 |